Supernus Pharma (SUPN) Cited for Making False or Misleading Claims About Risks Associated with Oxtellar XR

November 3, 2016 10:49 AM EDT

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Supernus Pharma (NASDAQ: SUPN) received a letter from the FDA for making false or misleading claims about risks associated with Oxtellar XR.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Trader Talk

Add Your Comment